Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 3;628(8009):872–877. doi: 10.1038/s41586-024-07266-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Authors 2024, corrected publication 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, Study schema. Participant eligibility was assessed during the screening period, followed by an observation period during which baseline PA disease status was monitored. The enrolment of participants into each cohort was staggered using a sentinel dosing strategy. Three participants were enrolled into a cohort, treated and monitored for safety for at least 14 days by a Safety Monitoring Committee. After confirmation that no DLTs occurred, enrolment and dosing of the next cohort began. After the treatment period, participants could roll over into the extension study or enter a two-year follow-up period. Q2W, every two weeks; Q3W, every three weeks. b, CONSORT diagram. ^aAn additional participant was enrolled in cohort 1 per protocol after the discontinuation of one participant after their first dose owing to the withdrawal of participant consent. ^bSeven individuals failed the initial screening; two of these individuals were rescreened and met eligibility criteria for inclusion in the study. ^cOne participant switched to 0.60 mg per kg every two weeks dosing.